ClariVest Asset Management’s Aldeyra Therapeutics ALDX Stock Holding History

ClariVest Asset Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-130,044	Closed	-$869K	–	873
2023 Q3	$869K	Hold	130,044	–	–	0.05%	260
2023 Q2	$1.09M	Buy	130,044 +23,588	+22%	+$232K	0.05%	234
2023 Q1	$1.06M	Buy	106,456 +56	+0.1%	+$396	0.05%	279
2022 Q4	$741K	Sell	106,400 -1,600	-1%	-$9.15K	0.04%	324
2022 Q3	$577K	Hold	108,000	–	–	0.03%	348
2022 Q2	$431K	Hold	108,000	–	–	0.02%	396
2022 Q1	$480K	Sell	108,000 -15,200	-12%	-$60.5K	0.02%	392
2021 Q4	$493K	Buy	123,200 +56,100	+84%	+$428K	0.02%	434
2021 Q3	$590K	Sell	67,100 -600	-0.9%	-$5.51K	0.02%	416
2021 Q2	$767K	Buy	+67,700	New	+$814K	0.03%	349

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClariVest Asset Management's ALDX Position: Q4 2023 in Review

ClariVest Asset Management sold out of Aldeyra Therapeutics (ALDX) in Q4 2023, closing a stake of 130,044 shares — an estimated $869K sold.

ClariVest Asset Management first reported a position in ALDX in Q2 2021 and held it in 10 quarters. The position peaked at $1.09M in Q2 2023. 105 funds tracked by Wall St. Rank hold ALDX as of Q4 2023.

ClariVest Asset Management reported no remaining Aldeyra Therapeutics position as of Q4 2023 after selling out during the quarter.
ClariVest Asset Management sold 130,044 Aldeyra Therapeutics shares in Q4 2023, an estimated $869K.
ClariVest Asset Management first reported a position in Aldeyra Therapeutics in Q2 2021 and held it in 10 quarters.
ClariVest Asset Management's Aldeyra Therapeutics position peaked at $1.09M in Q2 2023.
105 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2023.

Based on ClariVest Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.